Surrozen

Surrozen Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Surrozen (SRZN) as of Nov 21, 2026 is -494.82. In the previous year, Cash Conversion Cycle (CCC) was 9.59 — a change of -5,259.71% (lower).

Cash Conversion Cycle

-494.82

YoY

-5,259.71%

Last updated:

Cash Conversion Cycle (CCC) of Surrozen is 2025 -494.82 . Cash Conversion Cycle (CCC) of Surrozen was 2024 9.59 . It decreases by -5,259.71% lower compared to the previous year.

The Surrozen Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2020
-221.32 USD
Jan 1, 2021
-300.90 USD
Jan 1, 2022
-15.07 USD
Jan 1, 2023
55.80 USD
Jan 1, 2024
9.59 USD
Jan 1, 2025
-494.82 USD
The Surrozen Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-494.82-5,259.71%
9.59-82.81%
55.80-470.31%
-15.07-94.99%
-300.90+35.96%
-221.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Surrozen Stock analysis

What does Surrozen do? Surrozen, Inc. develops drug candidates targeting the Wnt pathway for tissue repair, focusing on multi-specific antibody-based therapeutics. The company's lead products SZN-1326, SZN-043, and SZN-413 are designed to mimic Wnt or R-spondin proteins, enhancing tissue repair mechanisms. Surrozen utilizes two core technologies: SWAP for mimicking Wnt proteins and SWEETS for amplifying the body's response to natural Wnt proteins. These therapeutics are developed for selective modulation of Wnt signaling across various organs and tissues. The company generates revenue through the development and potential future commercialization of its therapeutic candidates. Its lead products SZN-1326, SZN-043, and SZN-413 are in clinical stages, targeting conditions requiring tissue repair. Surrozen's technologies SWAP and SWEETS enable the creation of Wnt and R-spondin mimetics, which are central to its product pipeline. The firm's focus on selective Wnt pathway modulation positions it for partnerships or licensing deals with pharmaceutical companies seeking novel therapeutic approaches. Surrozen's target segments include patients requiring tissue repair in multiple organs, with its products designed to address conditions where Wnt signaling is critical. The company's clinical-stage pipeline focuses on developing therapeutics that selectively modulate Wnt signaling, aiming to provide solutions for tissue repair across various medical conditions. The firm's lead candidates SZN-1326, SZN-043, and SZN-413 are positioned for potential future market entry once clinical development progresses successfully. Surrozen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Surrozen stock

Cash Conversion Cycle (CCC) of Surrozen is -494.82 in 2025.

Cash Conversion Cycle (CCC) of Surrozen changed from 9.59 to -494.82, representing a -5,259.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Surrozen since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Surrozen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Surrozen

All Key Metrics — Surrozen